Alzheimer’s Disease/Dementia News

For those with either acute ischemic stroke or intracerebral hemorrhage, risk of dementia was three times higher after the first year and remained elevated as many as 20 years after, a speaker said at the International Stroke Conference.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.

Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s disease, deciding to discontinue development of Aduhelm and choosing to advance Leqembi.

Isaac Health has raised $5.7 million to help identify and care for individuals with different cognitive and brain health conditions in the United States.

A plasma phosphorylated-tau217 assay demonstrated a high degree of accuracy in identifying biomarkers consistent with Alzheimer’s disease-related pathology, according to research from JAMA Neurology.

A Houston-based neurohealth company has received a patent for its non-invasive, frequency-based deep brain stimulation device to address a range of psychiatric and neurologic conditions.

IGC Pharma has announced that dosing has commenced at one of its sites participating in a phase 2b clinical trial of a combination therapy for agitation in dementia related to Alzheimer’s disease.

“Is it all worth it?” reads the title of the Reddit post from an international medical graduate community. I wake up to these posts ever so frequently; I think to myself and slide the notification away.

Hearing loss was linked to a higher risk for dementia, and this risk was greater among people who did not use a hearing aid than those who did, a recent study in JAMA Otolaryngology – Head and Neck Surgery found.

Sleep fragmentation, rather than sleep duration or self-reported sleep quality, in early midlife was associated with worse executive function, fluency and cognition more than a decade later, according to research in Neurology.